Acurx Pharmaceuticals, Inc. (ACXP)

NASDAQ: ACXP · IEX Real-Time Price · USD
3.30
0.00 (0.00%)
Dec 5, 2022 1:18 PM EST - Market closed
Market Cap 38.26M
Revenue (ttm) n/a
Net Income (ttm) -11.46M
Shares Out 11.15M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,965
Open 3.36
Previous Close 3.3
Day's Range 3.16 - 3.53
52-Week Range 2.33 - 4.89
Beta n/a
Analysts Buy
Price Target 14.28 (+332.7%)
Earnings Date Nov 14, 2022

About ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, an... [Read more]

Industry Biotechnology
IPO Date Jun 25, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ACXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ACXP stock is "Buy." The 12-month stock price forecast is 14.28, which is an increase of 332.73% from the latest price.

Price Target
$14.28
(332.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

3 weeks ago - PRNewsWire

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and ...

STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 month ago - PRNewsWire

Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022

Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of C. difficile Infection (CDI) Emerging ibezapolstat microbiome data demonstrate th...

1 month ago - PRNewsWire

Acurx Announces Scientific Oral and Poster Presentations at IDWeek

New emerging, favorable microbiome data to be presented from previously completed Ph1 healthy volunteers and Ph2a patients with C. difficile Infection clinical trials Extends research on ibezapolstat's ...

1 month ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , Aug. 15, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

3 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and P...

STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

4 months ago - PRNewsWire

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Bi...

New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat New in vitro data show ibe...

4 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering

STATEN ISLAND, N.Y. , July 25, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotic...

4 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update

STATEN ISLAND, N.Y. , May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

6 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provi...

STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti...

7 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

8 months ago - PRNewsWire

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by...

STATEN ISLAND, N.Y., March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

8 months ago - PRNewsWire

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

STATEN ISLAND, N.Y., March 7, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

8 months ago - PRNewsWire

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectiou...

STATEN ISLAND, N.Y., Feb. 7, 2022 /PRNewswire/ --  Publication of study presents: Clinical results of 10 of 10 patients (100%) enrolled met the study's primary and secondary efficacy endpoints of Clinic...

9 months ago - PRNewsWire

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioi...

STATEN ISLAND, N.Y. , Dec. 6, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

11 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., Nov. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 year ago - PRNewsWire

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International...

STATEN ISLAND, N.Y. , Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 year ago - PRNewsWire

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provid...

STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 year ago - PRNewsWire

Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek

STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...

1 year ago - PRNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

1 year ago - PRNewsWire

Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

1 year ago - PRNewsWire

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster P...

STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

1 year ago - PRNewsWire

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, ...

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: A...

1 year ago - Newsfile Corp

Acurx Pharmaceuticals to Join the Russell Microcap Index®

STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 year ago - PRNewsWire

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 year ago - PRNewsWire